- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- August 2026
- 374 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- August 2026
- 273 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- August 2026
- 177 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- August 2026
- 379 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- November 2025
- 150 Pages
Global
From €3368EUR$3,750USD£2,877GBP
- Report
- June 2026
- 180 Pages
Global
From €4266EUR$4,750USD£3,644GBP
- Report
- May 2026
- 400 Pages
Global
From €4445EUR$4,949USD£3,797GBP
- Report
- January 2026
- 143 Pages
Global
From €3548EUR$3,950USD£3,031GBP
- Report
- November 2025
- 143 Pages
Global
From €3548EUR$3,950USD£3,031GBP
- Report
- November 2025
- 148 Pages
Global
From €3548EUR$3,950USD£3,031GBP
- Report
- February 2026
- 160 Pages
Global
From €2982EUR$3,320USD£2,547GBP
€3727EUR$4,150USD£3,184GBP
- Report
- October 2025
- 160 Pages
Global
From €2838EUR$3,160USD£2,424GBP
€3548EUR$3,950USD£3,031GBP
- Report
- October 2025
- 160 Pages
Global
From €2838EUR$3,160USD£2,424GBP
€3548EUR$3,950USD£3,031GBP
- Report
- March 2026
- 125 Pages
Global
From €4356EUR$4,850USD£3,721GBP

The Left Atrial Appendage Closure Device (LAACD) is a medical device used to reduce the risk of stroke in patients with atrial fibrillation. It is a minimally invasive procedure that involves the placement of a device in the left atrial appendage, a small pouch in the heart, to prevent blood clots from forming and entering the bloodstream. The device is designed to reduce the risk of stroke without the need for long-term anticoagulation therapy.
The LAACD market is a rapidly growing segment of the cardiovascular device market. It is estimated that the LAACD market will continue to grow due to the increasing prevalence of atrial fibrillation and the need for stroke prevention. The market is expected to benefit from technological advancements, such as the development of new devices and improved delivery systems.
Some of the major players in the LAACD market include Abbott, Boston Scientific, Medtronic, and St. Jude Medical. These companies are actively developing and marketing LAACD devices to meet the needs of patients with atrial fibrillation. Show Less Read more